[A18-50] Cariprazine (schizophrenia) - Addendum to Commission A18-25
Last updated 04.10.2018
Project no.:
A18-50
Commission:
Commission awarded on 22.08.2018 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Mental and emotional wellbeing
Adults with schizophrenia, outcome "akathisia"
Long-term treatment: In patients with mostly negative symptoms hint of a non-quantifiable added benefit. Remaining patients as well as acute treatment: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A18-25 | Cariprazine (schizophrenia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2018-10-04 A G-BA decision was published.